Align Tech (ALGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Erin Wright from Morgan Stanley maintained a Buy rating on the stock and has a $272.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Erin Wright has given his Buy rating due to a combination of factors that indicate positive growth prospects for Align Technology. The company’s recent discussions at a dental conference highlighted promising developments in innovation, particularly in scanners and the teen market segment, which are expected to drive growth as the overall market improves. Additionally, Align’s management has confirmed their 2025 guidance, which suggests a continued positive macro environment and clear aligner volume growth, enhancing confidence in the company’s future performance.
Furthermore, the upcoming launch of the iTero Lumina Restorative is anticipated to strengthen Align’s position in the GP channel, with positive feedback already emerging. Wright’s analysis also takes into account the valuation perspective, noting that Align’s shares are trading below historical levels, making them an attractive investment. This combination of market recovery signs, innovative product developments, and favorable valuation metrics supports Wright’s Buy rating for Align Technology.
Wright covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, UnitedHealth, and Zoetis. According to TipRanks, Wright has an average return of 13.6% and a 62.67% success rate on recommended stocks.
In another report released on February 14, Wells Fargo also initiated coverage with a Buy rating on the stock with a $255.00 price target.